Trials / Not Yet Recruiting
Not Yet RecruitingNCT07484269
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Understanding Drug Utilisation, Treatment Patterns, Clinical Outcomes, and Profile of the Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan for the Treatment of Metastatic Prostate Cancer: a Multicountry, AI-powered Registry (PULSE)
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 753 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Detailed description
This study is planned as a multicountry, non-interventional, longitudinal AI-enhanced digital registry that will leverage advanced data extraction technologies to efficiently generate RWD. The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer.
Conditions
Timeline
- Start date
- 2026-08-01
- Primary completion
- 2031-07-31
- Completion
- 2031-07-31
- First posted
- 2026-03-20
- Last updated
- 2026-03-20
Source: ClinicalTrials.gov record NCT07484269. Inclusion in this directory is not an endorsement.